Literature DB >> 19691086

Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.

Vincent Michael Riccardi1.   

Abstract

BACKGROUND: The disorder neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene, which influences the availability of activated Ras and the latter's control of cellular proliferation. Emphasis on this aspect of NF1 has focused attention on the tumor suppression function of NF1 and thereby displaced attention from the gene's role in initial normal tissue formation, maintenance, and repair.
METHODS: Clinical and neuroimaging data systematically compiled over more than 30 years are analyzed to document the involvement of multiple organs and tissues, often with an embryonic origin. In addition, recent literature based on selective knockout mouse experiments is cited to corroborate embryonic dysplasia as an element of NF1 pathogenesis.
RESULTS: Tissue dysplasia, both ab initio and as part of tissue maintenance and wound healing, is a key clinical and pathogenetic aspect of NF1 and thereby provides a rationale for differentiating the elements of NF1 into features, consequences, and complications.
CONCLUSIONS: NF1 is a histogenesis control gene that also has properties that overlap with those of a tumor suppressor gene. Both its neoplastic and dysplastic manifestations become more amenable to understanding and treatment if they are differentiated at three levels--specifically, features, consequences and complications. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19691086     DOI: 10.1002/bdra.20616

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  10 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

2.  Increased risk of breast cancer in women with NF1.

Authors:  Sara Aileen Madanikia; Amanda Bergner; Xiaobu Ye; Jaishri O'Neill Blakeley
Journal:  Am J Med Genet A       Date:  2012-11-19       Impact factor: 2.802

3.  Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey.

Authors:  Pamela L Wolters; Stephanie Reda; Staci Martin; Nour Al Ghriwati; Melissa Baker; Dale Berg; Gregg Erickson; Barbara Franklin; Vanessa L Merker; Beverly Oberlander; Stephanie Reeve; Claas Rohl; Tena Rosser; Mary Anne Toledo-Tamula; Ana-Maria Vranceanu
Journal:  Am J Med Genet A       Date:  2021-09-18       Impact factor: 2.578

Review 4.  The role of stem cells in benign tumors.

Authors:  Haiyan Qin; Dongyu Bao; Xin Tong; Qingang Hu; Guowen Sun; Xiaofeng Huang
Journal:  Tumour Biol       Date:  2016-09-21

5.  Multisystem burden of neurofibromatosis 1 in Denmark: registry- and population-based rates of hospitalizations over the life span.

Authors:  Line Kenborg; Anne Katrine Duun-Henriksen; Susanne O Dalton; Pernille E Bidstrup; Karoline Doser; Kathrine Rugbjerg; Camilla Pedersen; Anja Krøyer; Christoffer Johansen; Klaus Kaae Andersen; John R Østergaard; Hanne Hove; Sven Asger Sørensen; Vincent M Riccardi; John J Mulvihill; Jeanette F Winther
Journal:  Genet Med       Date:  2020-02-28       Impact factor: 8.822

6.  Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis.

Authors:  Araika Gutiérrez-Rivera; Haizea Iribar; Anna Tuneu; Ander Izeta
Journal:  Stem Cells Int       Date:  2012-04-01       Impact factor: 5.443

7.  Sphenoid Bone Pneumatisation on Lateral Cephalograms of Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Hannah T Scheuer; Jan F Kersten; Hanna A Scheuer
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

8.  Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.

Authors:  Karolina Kobus; Daniela Hartl; Claus Eric Ott; Monika Osswald; Angela Huebner; Maja von der Hagen; Denise Emmerich; Jirko Kühnisch; Hans Morreau; Frederik J Hes; Victor F Mautner; Anja Harder; Sigrid Tinschert; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.

Authors:  Frank L Rice; George Houk; James P Wymer; Sara J C Gosline; Justin Guinney; Jianqiang Wu; Nancy Ratner; Michael P Jankowski; Salvo La Rosa; Marilyn Dockum; James R Storey; Steven L Carroll; Phillip J Albrecht; Vincent M Riccardi
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.752

10.  Lower fasting blood glucose in neurofibromatosis type 1.

Authors:  Aline Stangherlin Martins; Ann Kristine Jansen; Luiz Oswaldo Carneiro Rodrigues; Camila Maria Matos; Marcio Leandro Ribeiro Souza; Juliana Ferreira de Souza; Maria de Fátima Haueisen Sander Diniz; Sandhi Maria Barreto; Leonardo Mauricio Diniz; Nilton Alves de Rezende; Vincent Michael Riccardi
Journal:  Endocr Connect       Date:  2015-12-02       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.